Navigation Links
VetStem Biopharma Shares the Story of San Fransisko Who Advanced in His Dressage Career After Being Treated with VetStem Cell Therapy

San Fransisko, or Sisko for short, is a German warmblood with an impressive pedigree. His owner, Deborah, purchased him at four years old to pursue a career in dressage. According to Deborah, dressage came easy to Sisko and his trainer commented that he was the most talented horse that she’d ever worked with. Unfortunately, Sisko suffered an injury while playing in his pasture. Deborah reported that he jammed his neck and suddenly refused to go forward leading Deborah to seek medical attention.

After several visits to an equine lameness expert and numerous diagnostic tests, it was determined that a few of Sisko’s neck vertebrae were malformed, causing pain in his neck and rendering him unable to work in his chosen field. Cervical facet disease can be caused by developmental conditions and/or injuries which can lead to osteoarthritis and spinal compression in the neck. Conventional treatments for the degenerative joints may reduce inflammation and pain but ongoing degeneration of the facet joints and their supportive structures can occur, leading to eventual worsening of pain and symptoms.

Fortunately, Sisko qualified for a clinical research program that is being conducted by VetStem to study the effects of VetStem Regenerative Cell Therapy on horses with cervical facet disease. To begin the process, Sisko’s veterinarian collected fat from Sisko’s tailhead and shipped it to the VetStem laboratory in San Diego, California for processing. VetStem laboratory technicians aseptically processed the fat to extract the stem cells and create injectable doses of Sisko’s own stem and regenerative cells. These doses were shipped back to Sisko’s veterinarian for injection into the affected joints and also intravenously. Due to the severity of Sisko’s case, he received a follow up treatment approximately six weeks after the initial treatment.

According to Deborah, Sisko began to improve and slowly went back to work after a lengthy rehab. He eventually regained complete mobility in his neck in both directions and was able to resume his training. In one year, he moved up from Training Level to First Level and in 2018, completed his first full year of showing. He ended the year as First Level Champion for the California Dressage Society, Temecula Valley Chapter, in both of their series of Rated and Schooling shows. He also won their award for High Score in a Single Test for both the Rated and Schooling shows as well as the Chapter’s Warmblood breed award. Deborah stated, “Without a doubt, Sisko would not have recovered and been able to resume his dressage career if he hadn’t received the stem cell treatments. I’m very grateful to my knowledgeable veterinarian for his continued help with Sisko and to VetStem for storing his stem cell reserves in case he needs them in the future.”

Stem cells are regenerative cells that can differentiate into many tissue types, reduce pain and inflammation, help to restore range of motion, and stimulate regeneration of tendon, ligament and joint tissues. Sisko’s case was handled under a VetStem clinical research program, in an effort to gain more information about stem cell use for this condition. Any inquiries regarding treatment of similar conditions or other non-orthopedic indications should be directed to VetStem clinical research personnel.

About VetStem Biopharma, Inc.
VetStem Biopharma is a veterinarian-lead Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 17,000 treatments by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a large portfolio of issued patents in the field of regenerative medicine.

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. VetStem Biopharma Launches Human Stem Cell Company in San Diego
2. VetStem Biopharma is Pleased to Announce Dr. Douglas Stramel of Advanced Care Veterinary Services is Successfully Using the Pall V-PET™ Platelet Therapy System
3. VetStem Biopharma is Pleased to Share the Success Story of Rascal who was Treated with VetStem Cell Therapy by Dr. Deborah Fegan
4. Veterinarian Dr. Patrick Leadbeater Brings VetStem Regenerative Cell Therapy to the Island of Kauai
5. VetStem Biopharma Shares News of the Successful Treatment of Partially Torn Cruciate Ligament in Young Labrador Retriever with the Pall V-PET™ Platelet Therapy System
6. VetStem Biopharma CEO, Dr. Robert Harman, will Present Data on Stem Cells for Kidney Disease in Poster Session at Feline Veterinary Conference
7. CEO of VetStem Biopharma, Dr. Robert Harman, to Present Results of Safety Study for Allogeneic Stem Cell Product at Regenerative Medicine Conference
8. New Patent for Adipose Stem Cells Issued to VetStem Biopharma
9. Dr. Bob Harman, CEO of VetStem Biopharma, Speaks on Stem Cells at Local Rotary Club
10. Dr. Bob Harman of VetStem Biopharma to Speak on the Business of Stem Cells at the Wild West Veterinary Conference
11. VetStem Biopharma CEO and Founder, Dr. Bob Harman, Interviewed in New Book "Stem Cell Therapy: A Rising Tide"
Post Your Comments:
(Date:2/5/2020)... ... February 04, 2020 , ... Shoreline Biome , a ... strain level, has announced a new distribution partnership in Asia. , The distribution ... to companies and research organizations in China, Hong Kong, and Macau. , Gene ...
(Date:1/28/2020)... ... January 28, 2020 , ... Genedata, ... the release of Genedata Expressionist ® 13.5 at the 2020 WCBP ... Methods (MAM) for characterizing and monitoring the quality of biopharmaceuticals throughout their ...
(Date:1/24/2020)... ... January 24, 2020 , ... The ... in biotechnology, diagnostics, therapeutics, laboratory and clinical services during the first two decades ... the world. And as Slone Partners celebrates its 20th anniversary this ...
(Date:1/22/2020)... ... January 21, 2020 , ... COBO Technologies and Cardea ... The partners have agreed to co-develop and market a portfolio of CRISPR QC ... programs. Over the longer-term, the parties aim to develop a COBO branded QC ...
Breaking Biology Technology:
(Date:1/22/2020)... ... 21, 2020 , ... Lifecycle Biotechnologies announces the new line of high purity powder ... based on their process requirements and accurately weighed to 0.001 of a gram. The new ... , Sugars , Carbohydrates , Phosphates , ...
(Date:1/8/2020)... Ariz. (PRWEB) , ... January 08, 2020 , ... ... therapies, is now offering complimentary overnight shipping to its nationwide practice network ... biologics, but also due to volume in its Network the biologics themselves are ...
(Date:1/2/2020)... , ... January 02, 2020 , ... ... semi-custom aqueous reagents, chemicals, and medias, as well as medical grade plastic products ... and tissue-based product manufacturers. , “We are excited to bring even more ...
Breaking Biology News(10 mins):